Abstract 17431: Plasma levels of n-3 Polyunsaturated Fatty Acids and Risk of Hospitalization in Patients with Non-Ischemic Cardiomyopathy
Purpose: n-3 polyunsaturated fatty acids (PUFAs) may lower cardiovascular (CV) risk by exerting antithrombotic, antiarrhythmic and anti-inflammatory effects. However, whether higher baseline (b) levels of PUFAs are associated with decreased risk of hospitalization (hosp) in patients (pts) with systolic dysfunction remains unknown. We investigated, in pts with non-ischemic cardiomyopathy (NICM), the associations between (b) levels of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acid and the risk of hosp. We hypothesized that higher levels of PUFAs are associated with a lower risk of hosp.
Methods: DHA and EPA levels were measured at (b) in 133 patients with NICM who participated in a randomized, placebo-controlled trial designed to test the effects of one-year supplementation with 2 g of n-3 PUFAs on left ventricular systolic function. Outcomes included all-cause hosp, CV hosp and hosp for heart failure (HF). For each hosp outcome, the response variable was treated as binary. Logistic regression models were used for each of the hospitalization outcomes. Interactions between DHA or EPA levels and treatment group were assessed; when significant, results for the whole cohort are not reported.
Results: The association between PUFAs levels and hosp are reported in Table. No significant interaction between DHA or EPA level and treatment group was found for all-cause hosp (p=0.19; and p=0.55, respectively) and for HF hosp (p=0.20; and p=0.55 respectively). For CV hosp, a significant interaction was found between DHA level and treatment group (p=0.05) but not between EPA level and treatment group (p=1.00).
Conclusion: In NICM pts higher (b) DHA and EPA levels are associated with lower probability of all-cause and HF hosp. Additionally, EPA levels are associated with lower risk of CV hosp. These findings suggest that (b) DHA and EPA levels may be a marker of risk of hosp in pts with NICM. Further studies are needed to investigate the mechanisms underlying these associations.
- © 2012 by American Heart Association, Inc.